Tạp chí Tim mạch học Việt Nam

Article detail

Article detail description

Home
BÀI TỔNG QUAN Issue: Số 123 - 2026 TIM MẠCH CAN THIỆP

Structural Heart Interventions: A New Era in Interventional Cardiology

Published: November 10, 2026
Views: 37
DOI 10.58354/jvc.123.2026.1397

Abstract

Structural heart interventions have evolved from shunt modification and balloon valvuloplasty into a broad catheter-based therapeutic ecosystem encompassing valvular, congenital, and selected heart-failure-related disorders. This narrative review examines the emergence of the field, historical milestones, contemporary evidence, and future directions. Transcatheter aortic valve implantation has the most mature randomized and long-term evidence, whereas mitral and tricuspid interventions and left atrial appendage occlusion require careful interpretation according to disease phenotype, anatomy, timing, and competing risks. Recent studies refine our understanding of valve durability, earlier intervention, heart failure outcomes, and antithrombotic strategies. Future frontiers include lifetime management, myocardial preservation, artificial intelligence, patient-specific simulation, transcatheter electrosurgery, biological disease modification, and patient-centered trial design. Sustainable progress requires linking technological innovation to demonstrable clinical benefit, equitable access, and multidisciplinary expertise.

Keywords
structural heart disease transcatheter intervention valvular heart disease lifetime management artificial intelligence precision medicine

References

1.
Marmagkiolis K, Caballero J, Votsis S, et al. Structural heart disease interventions. Year in review 2023-2024. Catheter Cardiovasc Interv. 2025;105(5):1196-1203. doi: 10.1002/ccd.31436.
DOI: doi.org/10.1002/ccd.31436
2.
Praz F, Borger MA, Lanz J, et al. 2025 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2025;46(44):4635-4736. doi: 10.1093/eurheartj/ehaf194.
DOI: doi.org/10.1093/eurheartj/ehaf194
3.
Kodali S. The structural heart revolution: how it started during my fellowship and how far it's come [lecture]. CRF Fellows Course; 2021.
4.
Vahl T. The structural heart revolution: perspectives from fellowship and beyond [lecture]. Columbia University Irving Medical Center.
5.
Beneki E, Grapsa J. Future of valvular heart disease and structural heart interventions: why so much excitement? J Pers Med. 2025;15(9):443. doi: 10.3390/jpm15090443.
DOI: doi.org/10.3390/jpm15090443
6.
Steinberg DH, Staubach S, Franke J, Sievert H. Defining structural heart disease in the adult patient: current scope, inherent challenges and future directions. Eur Heart J Suppl. 2010;12(Suppl E):E2-E9. doi:10.1093/eurheartj/suq012.
DOI: doi.org/10.1093/eurheartj/suq012
7.
Hahn RT, Lindenfeld J, Lim DS, et al. Structural cardiac interventions in patients with heart failure: JACC scientific statement. J Am Coll Cardiol. 2024;84(9):832-847. doi:10.1016/j.jacc.2024.05.061.
DOI: doi.org/10.1016/j.jacc.2024.05.061
8.
Rashkind WJ, Miller WW. Creation of an atrial septal defect without thoracotomy. A palliative approach to complete transposition of the great arteries. JAMA. 1966;196(11):991-992. doi: 10.1001/jama.1966.03100240125026.
DOI: doi.org/10.1001/jama.1966.03100240125026
9.
Inoue K, Owaki T, Nakamura T, et al. Clinical application of transvenous mitral commissurotomy by a new balloon catheter. J Thorac Cardiovasc Surg. 1984;87(3):394-402.
10.
Andersen HR, Knudsen LL, Hasenkam JM. Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs. Eur Heart J. 1992;13(5):704-708. doi: 10.1093/oxfordjournals.eurheartj.a060238.
DOI: doi.org/10.1093/oxfordjournals.eurheartj.a060238
11.
Bonhoeffer P, Boudjemline Y, Saliba Z, et al. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet. 2000;356(9239):1403-1405.
12.
Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106(24):3006-3008.
13.
Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597-1607. doi: 10.1056/NEJMoa1008232.
DOI: doi.org/10.1056/nejmoa1008232
14.
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705. doi:10.1056/NEJMoa1814052.
DOI: doi.org/10.1056/nejmoa1814052
15.
Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380(18):1706-1715. doi:10.1056/NEJMoa1816885.
DOI: doi.org/10.1056/nejmoa1816885
16.
Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364(15):1395-1406. doi:10.1056/NEJMoa1009355.
DOI: doi.org/10.1056/nejmoa1009355
17.
Leon MB, Mack MJ, Pibarot P, et al. Transcatheter or surgical aortic-valve replacement in low-risk patients at 7 years. N Engl J Med. 2026;394(8):773-783. doi: 10.1056/NEJMoa2509766.
DOI: doi.org/10.1056/nejmoa2509766
18.
Forrest JK, Yakubov SJ, Deeb GM, Reardon MJ. Six-year outcomes after transcatheter vs surgical aortic valve replacement in low-risk patients with aortic stenosis. J Am Coll Cardiol. 2026;87(23):3210-3221. doi: 10.1016/j.jacc.2026.02.5063.
DOI: doi.org/10.1016/j.jacc.2026.02.5063
19.
Thyregod HGH, Jørgensen TH, Ihlemann N, et al. Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial. Eur Heart J. 2024;45(13):1116-1124. doi:10.1093/eurheartj/ehae043.
DOI: doi.org/10.1093/eurheartj/ehae043
20.
Généreux P, Piazza N, Alu MC, et al. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. Eur Heart J. 2021;42(19):1825-1857. doi:10.1093/eurheartj/ehaa799.
DOI: doi.org/10.1093/eurheartj/ehaa799
21.
Généreux P, Schwartz A, Oldemeyer JB, et al. Transcatheter aortic-valve replacement for asymptomatic severe aortic stenosis. N Engl J Med. 2025;392(3):217-227. doi: 10.1056/NEJMoa2405880.
DOI: doi.org/10.1056/nejmoa2405880
22.
Loganath K, Craig NJ, Everett RJ, et al. Early intervention in patients with asymptomatic severe aortic stenosis and myocardial fibrosis: the EVOLVED randomized clinical trial. JAMA. 2025;333(3):213-221. doi:10.1001/jama.2024.22730.
DOI: doi.org/10.1001/jama.2024.22730
23.
Van Mieghem NM, Elmariah S, Spitzer E, et al. Transcatheter aortic valve replacement in patients with systolic heart failure and moderate aortic stenosis: TAVR UNLOAD. J Am Coll Cardiol. 2025;85(9):878-890. doi: 10.1016/j.jacc.2024.10.070.
DOI: doi.org/10.1016/j.jacc.2024.10.070
24.
Makkar RR, Thourani VH, Vahl TP, et al. Transcatheter aortic valve implantation with the Trilogy valve for symptomatic native aortic regurgitation (ALIGN-AR): a pivotal, multicentre, single-arm, investigational device exemption study. Lancet. 2025;406(10521):2757-2771. doi: 10.1016/S0140-6736(25)02215-9.
DOI: doi.org/10.1016/s0140-6736(25)02215-9
25.
Lønborg J, Jabbari R, Sabbah M, et al. PCI in patients undergoing transcatheter aortic-valve implantation. N Engl J Med. 2024;391:2189-2200. doi:10.1056/NEJMoa2401513.
DOI: doi.org/10.1056/nejmoa2401513
26.
Stähli BE, Ruschitzka F, Westermann D, et al. Timing of PCI in patients undergoing transcatheter aortic-valve implantation. N Engl J Med. 2026. doi: 10.1056/NEJMoa2606924.
DOI: doi.org/10.1056/nejmoa2606924
27.
Brouwer J, Nijenhuis VJ, Delewi R, et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med. 2020;383(15):1447-1457. doi:10.1056/NEJMoa2017815.
DOI: doi.org/10.1056/nejmoa2017815
28.
Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med. 2020;382(18):1696-1707. doi:10.1056/NEJMoa1915152.
DOI: doi.org/10.1056/nejmoa1915152
29.
Dangas GD, Tijssen JGP, Wöhrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med. 2020;382(2):120-129. doi:10.1056/NEJMoa1911425.
DOI: doi.org/10.1056/nejmoa1911425
30.
Dodgson CS, Herstad J, Kløve SF, et al. Anticoagulation monotherapy vs antiplatelet monotherapy after transcatheter aortic valve implant: the ACASA-TAVI randomized clinical trial. JAMA. 2026. doi: 10.1001/jama.2026.17036.
DOI: doi.org/10.1001/jama.2026.17036
31.
Kharbanda RK, Kennedy J, Jamal Z, et al. Routine cerebral embolic protection during transcatheter aortic-valve implantation. N Engl J Med. 2025;392(24):2403-2412. doi: 10.1056/NEJMoa2415120.
DOI: doi.org/10.1056/nejmoa2415120
32.
Smith RL, Lim DS, Gillam LD, et al. One-year outcomes from the CLASP IID randomized trial for degenerative mitral regurgitation. JACC Cardiovasc Interv. 2023;16(23):2803-2816. doi:10.1016/j.jcin.2023.10.002.
DOI: doi.org/10.1016/j.jcin.2023.10.002
33.
Stone GW, Abraham WT, Lindenfeld J, et al. Five-year follow-up after transcatheter repair of secondary mitral regurgitation. N Engl J Med. 2023;388(22):2037-2048. doi: 10.1056/NEJMoa2300213.
DOI: doi.org/10.1056/nejmoa2300213
34.
Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med. 2018;379(24):2297-2306. doi:10.1056/NEJMoa1805374.
DOI: doi.org/10.1056/nejmoa1805374
35.
Anker SD, Friede T, von Bardeleben RS, et al. Transcatheter valve repair in heart failure with moderate to severe mitral regurgitation. N Engl J Med. 2024;391(19):1799-1809. doi: 10.1056/NEJMoa2314328.
DOI: doi.org/10.1056/nejmoa2314328
36.
Baldus S, Doenst T, Pfister R, et al. Transcatheter repair versus mitral-valve surgery for secondary mitral regurgitation. N Engl J Med. 2024;391(19):1787-1798. doi:10.1056/NEJMoa2408739.
DOI: doi.org/10.1056/nejmoa2408739
37.
Tartaglia F, Antonelli G, Gitto M, et al. TMVR for the treatment of mitral regurgitation: a state-of-the-art review. Circ Cardiovasc Interv. 2025;18(10):e015298. doi: 10.1161/CIRCINTERVENTIONS.125.015298.
DOI: doi.org/10.1161/circinterventions.125.015298
38.
Khan JM, Babaliaros VC, Greenbaum AB, et al. Anterior leaflet laceration to prevent ventricular outflow tract obstruction during transcatheter mitral valve replacement. J Am Coll Cardiol. 2019;73(20):2521-2534. doi:10.1016/j.jacc.2019.02.076.
DOI: doi.org/10.1016/j.jacc.2019.02.076
39.
Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med. 2023;388(20):1833-1842. doi:10.1056/NEJMoa2300525.
DOI: doi.org/10.1056/nejmoa2300525
40.
Kar S, Makkar RR, Whisenant BK, et al. Two-year outcomes of transcatheter edge-to-edge repair for severe tricuspid regurgitation: the TRILUMINATE Pivotal randomized controlled trial. Circulation. 2025;151(23):1630-1638. doi: 10.1161/CIRCULATIONAHA.125.074536.
DOI: doi.org/10.1161/circulationaha.125.074536
41.
Hahn RT, Makkar R, Thourani VH, et al. Transcatheter valve replacement in severe tricuspid regurgitation. N Engl J Med. 2025;392(2):115-126. doi: 10.1056/NEJMoa2401918.
DOI: doi.org/10.1056/nejmoa2401918
42.
Hausleiter J, Stocker TJ, Geisler T, et al. Tricuspid-valve intervention in heart failure. N Engl J Med. 2026;395(14):1363-1373. doi: 10.1056/NEJMoa2606934.
DOI: doi.org/10.1056/nejmoa2606934
43.
Lakkireddy D, Thaler D, Ellis CR, et al. Amplatzer Amulet left atrial appendage occluder versus Watchman device for stroke prophylaxis (Amulet IDE): a randomized, controlled trial. Circulation. 2021;144(19):1543-1552. doi:10.1161/CIRCULATIONAHA.121.057063.
DOI: doi.org/10.1161/circulationaha.121.057063
44.
Goldsweig AM, Glikson M, Joza J, et al. 2025 SCAI/HRS clinical practice guidelines on transcatheter left atrial appendage occlusion. J Soc Cardiovasc Angiogr Interv. 2025;4:103783. doi:10.1016/j.jscai.2025.103783.
DOI: doi.org/10.1016/j.jscai.2025.103783
45.
Wazni OM, Saliba WI, Nair DG, et al. Left atrial appendage closure after ablation for atrial fibrillation. N Engl J Med. 2025;392(13):1277-1287. doi: 10.1056/NEJMoa2408308.
DOI: doi.org/10.1056/nejmoa2408308
46.
Doshi SK, Kar S, Nair DG, et al. Left atrial appendage closure or anticoagulation for atrial fibrillation. N Engl J Med. 2026;394(21):2083-2094. doi: 10.1056/NEJMoa2517213.
DOI: doi.org/10.1056/nejmoa2517213
47.
Landmesser U, Skurk C, Kirchhof P, et al. Left atrial appendage closure or medical therapy in atrial fibrillation. N Engl J Med. 2026;394(13):1270-1280. doi: 10.1056/NEJMoa2513310.
DOI: doi.org/10.1056/nejmoa2513310
48.
Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2021;42(6):563-645. doi:10.1093/eurheartj/ehaa554.
DOI: doi.org/10.1093/eurheartj/ehaa554
49.
Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377(11):1011-1021. doi: 10.1056/NEJMoa1705915.
DOI: doi.org/10.1056/nejmoa1705915
50.
Faza NN, Özden Tok Ö, Hahn RT. Imaging in structural heart disease: the evolution of a new subspecialty. JACC Case Rep. 2019;1(3):440-445. doi:10.1016/j.jaccas.2019.08.012.
DOI: doi.org/10.1016/j.jaccas.2019.08.012
51.
Agricola E, Ancona F, Brochet E, et al. The structural heart disease interventional imager rationale, skills and training: a position paper of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2021;22(5):471-479. doi:10.1093/ehjci/jeab005.
DOI: doi.org/10.1093/ehjci/jeab005
52.
Leuzzi F, Formisano C, Cerrato E, et al. Intracardiac echocardiography in structural heart interventions: a comprehensive overview. J Clin Med. 2026;15(3):926. doi: 10.3390/jcm15030926.
DOI: doi.org/10.3390/jcm15030926
53.
Lauck SB, Clark C, Offen S, et al. Advancing the contemporary multidisciplinary heart valve team: update on priorities for clinicians and programs. Struct Heart. 2025;9(7):100490. doi: 10.1016/j.shj.2025.100490.
DOI: doi.org/10.1016/j.shj.2025.100490
54.
Shah SJ, Borlaug BA, Chung ES, et al. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. Lancet. 2022;399(10330):1130-1140. doi: 10.1016/S0140-6736(22)00016-2.
DOI: doi.org/10.1016/s0140-6736(22)00016-2
55.
Stone GW, Lindenfeld J, Rodés-Cabau J, et al. Interatrial shunt treatment for heart failure: the randomized RELIEVE-HF trial. Circulation. 2024;150(24):1931-1943. doi:10.1161/CIRCULATIONAHA.124.070870.
DOI: doi.org/10.1161/circulationaha.124.070870
56.
Fong FK, So KCY. The next era of transcatheter electrosurgery for structural heart interventions. JACC Case Rep. 2026;31(13):107382. doi: 10.1016/j.jaccas.2026.107382.
DOI: doi.org/10.1016/j.jaccas.2026.107382
57.
Khan JM, Greenbaum AB, Babaliaros VC, et al. The BASILICA trial: prospective multicenter investigation of intentional leaflet laceration to prevent TAVR coronary obstruction. JACC Cardiovasc Interv. 2019;12(13):1240-1252. doi:10.1016/j.jcin.2019.03.035.
DOI: doi.org/10.1016/j.jcin.2019.03.035
58.
Dhingra LS, Aminorroaya A, Sangha V, et al. Ensemble deep learning algorithm for structural heart disease screening using electrocardiographic images: PRESENT SHD. J Am Coll Cardiol. 2025;85(12):1302-1313. doi:10.1016/j.jacc.2025.01.030.
DOI: doi.org/10.1016/j.jacc.2025.01.030
59.
Poterucha TJ, Hughes JW, Brener MI, et al. AI-ECG detection of structural heart disease in the community setting: transportability and spectrum effects in the PREVUE-VALVE study. J Am Coll Cardiol. 2026;88(7):752-764. doi:10.1016/j.jacc.2026.06.013.
DOI: doi.org/10.1016/j.jacc.2026.06.013
60.
Allaham H, Chahal D, Srivastava M, et al. Clinical applications of artificial intelligence in structural heart disease. J Soc Cardiovasc Angiogr Interv. 2026;5(4):104396. doi:10.1016/j.jscai.2026.104396.
DOI: doi.org/10.1016/j.jscai.2026.104396
61.
Lederman RJ, Greenbaum AB, Halaby RN, et al. Fatal steam pop complicating investigational SESAME transcatheter myotomy using off-the-shelf equipment. Circ Cardiovasc Interv. 2026;19(2):e016252. doi:10.1161/CIRCINTERVENTIONS.125.016252.
DOI: doi.org/10.1161/circinterventions.125.016252
62.
Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368(6):503-512. doi:10.1056/NEJMoa1109034.
DOI: doi.org/10.1056/nejmoa1109034

Tác giả

Phạm Mạnh Hùng: Trường Đại học Y Hà Nội; Trần Đình Tuyên: Trường Đại học Y Hà Nội; Phạm Lê Minh: Trường Đại học Y Hà Nội; Phạm Nhật Minh: Trường Đại học Y Hà Nội; Nguyễn Ngọc Quang: Hệ thống Y tế Vinmec;
Structural Heart Interventions: A New Era in Interventional Cardiology

Files

PDF
Article Views37
Document Views0
Downloads5
Section BÀI TỔNG QUAN
Issue Số 123 - 2026
Category TIM MẠCH CAN THIỆP
Pages 5-27
Copyright Holder 2026 Tạp chí Tim mạch học Việt Nam

Related articles section label

Related articles

Related articles category hint

More articles

Vitamin B12 Deficiency - A Modifiable Cause of Erythropoietin-Resistant Anemia in Patients with Chronic Kidney Disease and Heart Failure: A Case Report

Background: Patients with chronic kidney disease (CKD) are at very high cardiovascular risk, with heart failure and anemia being two common conditions that significantly affect prognosis. Anemia in CKD is often attribute...

Chi tiết bài báo
PDF
DOI: 10.58354/jvc.123.2026.1416
49
Phạm Thị Ngọc Bích; Nguyễn Quốc Thành; Trần Trung Kiên; Nguyễn Dân Phúc